Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
Populations who should not use BPC-157: Pregnant or breastfeeding individuals (no safety data), anyone with a history of cancer (theoretical concern given pro-angiogenic mechanisms), individuals taking anticoagulants (some animal data suggest effects on platelet aggregation pathways), and anyone without access to sterile technique for injection preparation
These products are for laboratory research only and not intended for medical use
Patients with reasonable life expectancy who have dysplastic BE (confirmed by an expert gastrointestinal pathologist) should undergo endoscopic resection (with EMR or ESD) of all visible lesions and subsequent endoscopic ablation of residual flat BE mucosa Goal of endoscopic eradication therapycomplete eradication of all intestinal metaplasia Risk Stratification of BE The histologic finding of dysplasia (LGD or HGD) is the best clinical tool for identifying patients at risk for progression to EAC
At our clinic, the patients who respond best to BPC-157 for gut indications fall into three groups
US$ 21.81
US$ 23.29
US$ 26.11
US$ 20.41
US$ 25.87
US$ 23.31
US$ 28.60
US$ 23.49